Verve Therapeutics Inc.

04/04/2022 | Press release | Archived content

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic[...]